rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Deepika Pakianathan

Director

Company insider

Files Form 4 as: Director, Theravance Biopharma; Director, Karyopharm Therapeutics; Director, Mereo BioPharma Group; Director and 10% owner, Calithera Biosciences; Director, Pardes Biosciences; Director, OncoMed Pharmaceuticals; Director and 10% owner, Alder Biopharmaceuticals; Director, Alexza Pharmaceuticals.

Every Form 4 they filed

In numbers

Trades disclosed
194
Buys
12
Sells
11
Bought
$26.0M
Sold
$5.6M
Companies
9
Companies where not an officer
9
First trade
8 Mar 2006
Last trade
23 Sep 2026
Last filed
24 Sep 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
Theravance BiopharmaDirector · Pharmaceuticals · last 23 Sep 20260 buys · 0 sells
KPTI Karyopharm TherapeuticsDirector · Biotechnology · last 21 May 20265 buys · 9 sells
MREO Mereo BioPharma GroupDirector · Biotechnology · last 26 Feb 20260 buys · 1 sell
Calithera BiosciencesDirector, 10% owner · last 27 Jan 20231 buy · 1 sell
Pardes BiosciencesDirector · last 23 Dec 20210 buys · 0 sells
OncoMed PharmaceuticalsDirector · last 23 Apr 20194 buys · 0 sells
Alder BiopharmaceuticalsDirector, 10% owner · last 23 May 20181 buy · 0 sells
Alexza PharmaceuticalsDirector · last 21 Jun 20161 buy · 0 sells
TNDM Tandem Diabetes Care10% owner · Medical Devices · last 19 Nov 20130 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
23 Sep 2026filed 24 Sep 2026Theravance BiopharmaPharmaceuticalsSEC FORM 4 Code D—58,065filing
23 Sep 2026filed 24 Sep 2026Theravance BiopharmaPharmaceuticalsSEC FORM 4 Code D—6,009filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—17,000filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—17,000filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—6,000filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—28,000filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—22,044filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—23,576filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—24,258filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—13,398filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—6,000filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—28,000filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—22,044filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—23,576filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—24,258filing
23 Sep 2026filed 24 Sep 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code D—13,398filing
23 Sep 2026filed 24 Sep 2026Theravance BiopharmaPharmaceuticalsSEC FORM 4 Code D—58,065filing
23 Sep 2026filed 24 Sep 2026Theravance BiopharmaPharmaceuticalsSEC FORM 4 Code D—6,009filing
12 Jun 2026filed 16 Jun 2026Theravance BiopharmaPharmaceuticalsSEC FORM 4 Code A—6,009 at $0.00filing
12 Jun 2026filed 16 Jun 2026Theravance Biopharmaoption or derivative · PharmaceuticalsSEC FORM 4 Code A—13,398 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Health Care15
Not placed8

Buys in green, sells in red, by the company’s sector.

Related people

Kristin AbateChief Accounting Officer · Chief Accounting Officer at Karyopharm Therapeutics, filing Form 4 there in the last year
Weiss Asset Management LPOther role · Other at Theravance Biopharma, filing Form 4 there in the last year
Dean J. MitchellDirector · Director at Theravance Biopharma, filing Form 4 there in the last year
Rick E. WinninghamChief Executive Officer · Chief Executive Officer at Theravance Biopharma, filing Form 4 there in the last year
Alsup Laurie SmaldoneDirector · Director at Theravance Biopharma, filing Form 4 there in the last year
Stuart PoultonEVP, Chief Development Officer · Also traded KPTI in the last 90 days